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To compare the antihypertensive and humoral effects of 
the angiotensin-converting enzyme inhibitors captopril 
and enalapril, 20 patients with essential hypertension, 
not receiving treatment for 2 weeks and consuming a 
prescribed sodium ion intake, were randomly assigned 
to two parallel, double-blind treatment groups with 
stratification based on race and untreated seated dia•
stolic blood pressure. These groups received a placebo 
(day -1) followed by either captopril, 200 mg every 12 
hours (n = 9), or enalapril maleate, 20 mg every 12 hours 
(n = 11), alone (days 1 to 14) and then with hydro•
chlorothiazide, 25 mg every 12 hours (days 16 to 28). 
Captopril and enalapril were coadministered alone (day 
15) and with hydrochlorothiazide (day 29) to assess 
whether further decreases in blood pressure would oc•
cur. Captopril and enalapril alone caused comparable 
Angiotensin-converting enzyme inhibitors are a new class 
of antihypertensive agents. Captopril, the first orally active 
agent in this class, was marketed in the United States in 
1981. Enalapril (MK-421), a more potent orally active con•
verting enzyme inhibitor, will soon be marketed in the United 
States (l). Enalapril differs structurally from captopril by 
the absence of a mercapto or sulfhydryl group. This chem•
ical group, although initially deemed necessary for adequate 
converting enzyme inhibition, has been suggested to have 
a causal role in some of the adverse effects of captopril (2). 
Although captopril and enalapril clearly inhibit angio•
tensin-converting enzyme, the precise mechanisms respon•
sible for their blood pressure-lowering effects are contro•
versial 0-3). Other activities that have been suggested to 
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decreases (p < 0.05) in the mean 12 hour time-averaged 
seated diastolic blood pressure from values on day - 1 
(placebo), on day 1 (11 and 9 mm Hg, respectively) and 
day 14 (8 and 7 mm Hg, respectively). The addition of 
hydrochlorothiazide further decreased (p < 0.05) ~Iood 
pressure in each group (i and 8 mm Hg, respectively) 
from values on day 14. Combined use of captopril and 
enalapril did not result in further reduction. 
Coupled with the comparable changes observed in 
each treatment group in serum angiotensin-converting 
enzyme activity, plasma renin activity and plasma al•
dosterone concentration, these data support the view 
that captopril and enalapril have similar antihyperten•
sive effects and mechanisms. 
(J Am Coil CardioI1986;7:651-60) 
contribute include the p~t~ntiation of kinins, alterations in 
vasoactive prostaglandins and an interaction with the sym•
pathetic nervous system through the decrease in angio•
tensin II formation. It has also been suggested (3) that in•
hibition of converting enzyme in various tissues. such as 
arteriolar vessel walls. may be of more importance than 
inhibition of the circulating enzyme. 
Investigators have wondered whether captopril and en•
alapril might differ not only in potency but also in their 
antihypertensive effects as a result of dissimilarities in an•
cillary properties or tissue penetration, or both. Comparative 
studies in animals (4-10) have suggested either comparable 
effects or potential differences in the blood pres sure•
lowering or other actions of these agents. A difference 
between the effects of these agents on vasoactive prosta•
glandins in humans was noted by the same laboratory (11,12). 
Thind et al. (13) recently reported that in a double-blind 
parallel study of enalapril and captopril in 32 patients with 
moderate to severe hypertension receiving hydrochlorothia•
zide. enalapril was somewhat mqre effective than captopril 
in lowering blood pressure. acutely and chronically. In con-
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trast, Lewis et al. (14), in 24 hypertensive patients treated 
with hydrochlorothiazide in a trial of nearly identical design, 
reported that captopril was more effective than enalapril in 
the short term, but the two agents had comparable blood 
pressure-lowering effects after long-term treatment. More•
over, Chrysant et al. (IS) noted no difference between these 
agents in 20 hypertensive patients studied under a similar 
protocol. 
The purpose of this study was to compare the antihy•
pertensive effects of captopril and enalapril, both alone and 
in combination with a thiazide diuretic agent, in patients 
with mild to moderate essential hypertension. To assess 
possible mechanistic differences, doses of captopril and en•
alapril near the upper recommended ranges were selected, 
and the agents were coadministered to determine whether a 
further decrease in blood pressure would occur. 
Methods 
Patients. Twenty patients with essential hypertension 
and normal renal function qualified to participate in the 
study. These patients were recruited from our hypertension 
clinic population, on a sequential basis, if they were: 1) 
previously shown to be hypertensive (seated diastolic pres•
sure >95 mm Hg) while not receiving medications; 2) in 
otherwise good health based on their medical history, phys•
ical examination, electrocardiogram and laboratory organ 
function test evaluations; and 3) willing to participate in the 
study after a careful explanation of its purpose and their 
requested time commitment. All patients who volunteered 
gave written consent to participate after the trial was ap•
proved by the Jefferson University Institutional Review Board. 
Trial design (Fig. 1). All patients entered an initial 2 
week no drug period. During this time, they were instructed 
on a "no added salt" diet. Urinary excretion was monitored 
to exclude marked sodium restriction or excessive con-
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sumption. On study day - 1, patients were admitted to the 
clinical pharmacology unit at 8 AM, having fasted from the 
previous evening. An intravenous catheter was placed in an 
arm vein to allow blood sampling for humoral measure•
ments. Approximately 1 hour later, baseline determinations 
of supine and seated blood pressure and pulse rate were 
determined. For the purpose of objectivity and elimination 
of observer variation and fatigue, this and all other blood 
pressure and pulse rate measurements were made by a sta•
tionary, automated device that uses the Doppler principle 
(DINAMAP, Critikon, Inc.). In a single-blind manner, pa•
tients then received a placebo while fasting, and had blood 
pressure and pulse rate determined hourly for 12 hours. Food 
was withheld for 3 hours after dosing. The frequent eval•
uations were undertaken to minimize the effect of the known 
hour to hour within-subject variability in blood pressure on 
the assessment of overall treatment effects. Blood samples 
for determination of serum angiotensin-converting enzyme 
activity, plasma renin activity and aldosterone concentration 
were collected, after the patients had been seated for at least 
30 minutes, before dosing and at 1,4, 8 and 12 hours after 
dosing; blood samples were assayed at the completion of 
the trial. Urine was collected for 24 hours after placebo 
administration in two 12 hour fractions. 
At the end of the placebo day, the average seated diastolic 
blood pressure from 1 to 12 hours after dosing, that is, the 
mean of 12 separate readings, was computed for each pa•
tient. Patients continued on to the captoprillenalapril com•
parison (Fig. 1) if this mean value was between 94 and 120 
mm Hg. Because other investigators had suggested that the 
antihypertensive response of converting enzyme inhibitors 
might vary between black and white patients (16) or as a 
function of the level of the initial untreated blood pressure 
(17), patients were allocated study medications in a ran•
domized, double-blind manner to allow stratification for 
both of these variables into two comparable, parallel treat•
ment groups. 
Study Days: -1 1 .............. _ ............... _ .. 1 4_._1 5_.1 6 .--.-.......................... 2 8 .... 2 9 
2 Weeks 
No-Drug 
Period 
G r 0 u p C ( n=9 ) 
Captopril 
\'\ Group E (n=11) 4~ ________________________________ --, 
Enalapril 
Figure 1. Study protocol. Refer to text for doses. 
Cap = captopril; Enal = enalapriI; HCTZ = hy•
drochlorothiazide; PL = placebo. 
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Table 1 depicts the demographic characteristics of the 
two treatment groups (C for the group initially receiving 
captopril and E for the one initially receiving enalapril). In 
generaL the groups were well matched except for sex; how•
ever, this variable has not been noted to be a determinant 
of the blood pressure response to converting enzyme inhib•
itors. The unequal number of subjects in the two treatment 
groups was the result of the stratification procedure. One 
patient in group E was eliminated from the study on day 
25 and one patient in group C did not participate on day 29 
because of an excessive decrease in blood pressure (see 
Results section, Adverse effects). The data from these pa•
tients were included for comparisons before these days. 
The treatment sequences are shown in Figure 1. Each 
group received one of the converting enzyme inhibitors alone 
for 14 days, with inpatient evaluations and collection of 
study data similar to the placebo day (day - I) on the first 
and last day of monotherapy (days I and 14). The doses of 
captopril (200 mg every 12 hours) and enalapril maleate (20 
mg every 12 hours) were selected to approximate the max•
imal daily dosage recommended by the respective manu•
facturers. This was done to minimize the effects of the 
known potency difference between the two compounds in 
the efficacy comparison. All doses were prescribed for use 
on an "empty stomach." On study day 15, also an inpatient 
evaluation day, the other converting enzyme inhibitor was 
coadministered with the agent that the patient had been 
receiving; that is, the patients received both converting en•
zyme inhibitors, to test whether an additional hypotensive 
effect could be elicited. 
From day 16 to day 28, the patients received their original 
converting enzyme inhibitor in combination with hydro•
chlorothiazide, 25 mg every 12 hours, with an inpatient 
evaluation on the last day of treatment. A few patients were 
Table 1. Patient Characteristics of the Two Study 
Treatment Groups 
No of patients 
Age (yr) 
Mean (± SO) 
Range 
Sex 
Female 
Male 
Race (no. of patients) 
Black 
White 
Group C 
(captopril sequence) 
9 
47 ± 8 
39 to 61 
5 
4 
Group E 
(enalapril sequence) 
II 
54 ± 9 
42 to 64 
10 
Time (I to 12 hour)-Averaged Seated DiastolIc 
Blood Pressure on Placebo Day (mm Hg) 
94 to 105 106 to 120 94 to 105 106 to 120 
4 
2 
2 4 
3 
3 
I 
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allowed to proceed to the diuretic phase even if the mean 
seated diastolic presure was somewhat below 90 mm Hg 
(and they, thus, might not have received the drug under 
clinical circumstances), to allow the pharmacologic assess•
ment of the hypotensive activity of each converting enzyme 
inhibitor with the diuretic agent. On the next inpatient day 
(day 29), each subject received his or her original converting 
enzyme inhibitor, hydrochlorothiazide and a single dose of 
the other converting enzyme inhibitor to again test whether 
an additional hypotensive effect could be elicited. 
Patients were carefully evaluated during the study for 
drug-related side effects or changes in laboratory screening 
tests. Medication diaries, pill counts and retrospective eval•
uation of serum angiotensin-converting enzyme activity were 
used to assess compliance. 
Analyses. Plasma renin activity at pH 7.4 (Roche Di•
agnostics) and plasma aldosterone concentrations (Abbott 
Laboratories) were measured by radioimmunoassay meth•
ods. Angiotensin-converting enzyme activity was measured 
based on the percent of a known quantity of radiolabeled 
substrate (c'H)-hippuryl-glycyl-glycine) which was hydro•
lyzed in the presence of a known volume of a patient's 
serum per unit time (18). Sodium metabisulfite (50 ILl of a 
5% solution) was added to all blood samples for converting 
enzyme activity determinations to prevent degradation of 
captopril. Interassay variation was assessed daily using plasma 
or serum from normal subjects. Serum and urine electrolyte 
concentrations were determined by flame photometry. 
Statistical analysis. The overall treatment effect for each 
group during the dosing interval on each inpatient study day 
was characterized by calculating the mean of each patient's 
time-averaged 1 to 12 hour seated systolic and diastolic 
blood pressures and pulse rate. Within each treatment group 
separately, the differences in the means of these variables 
between study days were assessed using an analysis of vari•
ance procedure. The statistical model employed partitioned 
th~ error term to evaluate the effects of day (differences 
between study days during each treatment sequence), race, 
day x race interaction and subjects. If day (that is, treatment 
regimen differences on a given day [Fig. 1]) effects were 
significant, Duncan's multiple range test was used to com•
pare mean values by day in each treatment sequence. The 
differences between treatment groups for each study day 
were assessed by unpaired Student's t tests. When signifi•
cant differences in mean time-averaged diastolic blood pres•
sures either within or between the randomized treatment 
regimens were not observed, the differences that could have 
been detected with 80% power based on a t distribution 
were calculated. 
Statistical analysis of the humoral values was performed 
in a similar manner with the exception that, because of the 
unequal blood collection intervals, the average value for a 
patient on a treatment day was assessed by calculating the 
area under the respective variable time curve and dividing 
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by the time interval. The relations between the acute (day 
1) and chronic (day 14) blood pressure responses in each 
treatment group and various sruuy variables (for example, 
pretreatment blood pressure and y!::.sma renin activity) were 
evaluated by linear regression analysis. All statistical eval•
uations were made using a computer software package (Sta•
tistical Analysis Systems). Data are presented as the 
mean ± SD. All statistical tests were two-tailed and eval•
uated at a probability (p) ofless than 0.05 level of significance. 
Results 
Blood pressure. The means (± SD) of the time-aver•
aged systolic and diastolic pressures for each treatment group 
on each inpatient study day are depicted in Figure 2. The 
two treatment groups were well matched with regard to 
seated diastolic pressures on day - 1 (placebo day): group 
C (captopril sequence) 101 ± 6 mm Hg versus group E 
(enalapril sequence) 102 ± 8 mm Hg (p = 0.78). Systolic 
pressure was higher in group E than in group C but this 
difference was not quite significant (p = 0.08). The re•
mainder of the Results section will only address effects on 
diastolic blood pressure. 
Both captopril and enalapril alone lowered mean time•
averaged, seated diastolic bloou pressure on days 1 and 14 
in comparison with day -1 (placebo). Values on day 1 
(group C 90 ± 9 mm Hg versus group E 93 ± 9 mm Hg) 
and day 14 (group C 93 ± 8 mm Hg versus group E 
95 ± 10 mm Hg) within and between groups were com•
parable. The t test comparing the mean diastolic pressure 
on captopril or enalapril on day 14 could detect a 12 mm 
Hg difference with 80% power. 
Comparison of the time course of the hourly mean blood 
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pressure values for each group on study days - I and 1 
(data not shown) revealed that both agents had a prompt 
onset of action with a duration that extended throughout the 
12 hour dosing interval. Both onset of effect (1 versus 2 
hours) and maximal effect (2 versus 3 hours) were achieved 
slightly earlier with captopril than with enalapril. Compar•
ison of the time-averaged seated diastolic blood pressure for 
individuals receiving placebo (day -1) versus their values 
on the last day of monotherapy (day 14) revealed that 7 of 
9 patients in group C (captopril sequence) and 7 of 11 
patients in group E (enalapril sequence) had at least a de•
crease in mean time-averaged blood pressure of 5 mm Hg 
greater than the placebo response. 
Combined administration of captopril and enalapril on 
day J 5 did not decrease mean time-averaged seated diastolic 
pressure significantly from values observed on day 14: group 
C 93 ± 8 versus 91 ± 9 mm Hg, respectively, and group 
E 95 ± 10 versus 92 ± 11 mm Hg, respectively. Differ•
ences of 8 mm Hg (group C) and 9 mm Hg (group E) could 
be detected with 80% power for a paired comparison of the 
day 14 versus day 15 response. 
The addition of hydrochlorothiazide (Fig. 2) resulted in 
significant further decreases in mean time-averaged seated 
diastolic pressure within each group on day 28 (group C 
86 ± 12 mm Hg versus group E 87 ± 10 mm Hg), but 
differences between groups on this day were not statistically 
significant. 
With converting enzyme inhibitor plus diuretic therapy 
(day 28), 6 of 9 patients in group C and 7 of 10 patients in 
group E had time-averaged seated diastolic pressures less 
than 90 mm Hg. On day 29, when both converting enzyme 
inhibitors and hydrochlorothiazide were coadministered, the 
mean time-averaged seated diastolic pressure was similar 
for group C (82 ± 9 mm Hg) and for group E (82 ± 9 
29 
Figure 2. Mean time-averaged seated blood pres•
sures on inpatient study days in group C (captopril 
sequence, closed bars) and group E (enalapril se•
quence, open bars). The top of each bar indicates 
the mean systolic pressure whereas the bottom rep•
resents the mean diastolic pressure; the lines ex•
tending from each end of the bars depict I SD 
about each mean. Within group comparisons, p < 
0.05 for: * = from day - 1 (placebo); x = from 
days - 1, I. 14 and 15; and t = from day 28. 
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mm Hg). From day 28 to 29 within groups, however, seated 
diastolic blood pressure was significantly decreased in group 
E (p < 0.05) and nearly as decreased for group C. 
Heart rate. There were no significant changes in the 
mean time-averaged seated pulse rates on days - I, 1, 14 
or 15 within either treatment group. The respective mean 
values (beats/min) in group C (captopril sequence) were 69, 
68,69 and 70 whereas those in group E (enalapril sequence) 
were 67, 68, 68 and 70. Addition of hydrochlorothiazide 
(days 28 and 29) resulted in small (6 to 11 beats/min) but 
significant (p < 0.05) increases in mean pulse rate from 
day - 1 in each group. 
Laboratory values. After dietary counseling, mean so•
dium excretion on day - 1 was 86 mEq in group C and 125 
mEq in group E; these values were not quite significantly 
different and, overall, reflected compliance with the dietary 
prescription. Sodium excretion on day I in both groups was 
nearly identical to day - 1 values but was somewhat in•
creased, although not significantly, on days 14 and IS. On 
day 28, after 13 days of combined converting enzyme in•
hibitor plus hydrochlorothiazide treatment, mean urinary 
sodium excretion was 169 mEq in group C and 192 mEq 
in group E. Because urine was collected for only 12 hours 
on day 29, evaluation of mean 12 hour (9 AM to 9 PM) urine 
collections on days 28 and 29 revealed sodium values of 
104 and 77 mEq for group C (NS) and 105 and 66 mEq for 
group E (p < 0.05). Mean serum potassium did not change 
significantly from day - 1 to days 1, 14 and 28 in either 
group; values in group C were 4.0, 4.2, 4.1 and 3.9 mEq/liter 
whereas those in group E were 4.2,4.3,4.2 and 4.0 mEq/liter. 
The values for mean (± SD) time-averaged serum an•
giotensin-converting enzyme activity, plasma renin activity 
and plasma aldosterone concentration for each treatment 
group are depicted in Figure 3. On day -1 (placebo), mean 
angiotensin-converting enzyme activity (Fig. 3, top panel) 
was somewhat greater in group C than in group E (p = 
0.16). In comparison with the placebo day, both captopril 
and enalapril markedly suppressed mean converting enzyme 
activity on all subsequent days. No significant difference 
was observed between the two treatment sequences on any 
day. 
Mean time-averaged plasma renin activity (Fig. 3, mid•
dle panel) increased slightly though not significantly after 
both captopril and enalapril alone (days 1 and 14 in each 
group) versus placebo (day - I). No significant change from 
day 14 was observed on day IS (combined converting en•
zyme inhibitor administration) in either group. Addition of 
hydrochlorothiazide resulted in a marked increase (p < 0.05 
from all other days) in mean plasma renin activity in both 
groups on days 28 and 29; no significant change was ob•
served in either group when the alternate converting enzyme 
inhibitor was added to double therapy of converting enzyme 
inhibitor plus hydrochlorothiazide (day 28 to day 29). 
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Mean time-averaged plasma aldosterone concentration 
on day -] (placebo) (Fig. 3, bottom panel) was greater in 
group C than in group E. Both captopril and enalapril tended 
to decrease mean plasma aldosterone concentration on days 
1, 14 and 15 in comparison with their respective placebo 
days, although the changes did not always achieve statistical 
significance. No significant change in either group was seen 
with the addition of the alternate converting enzyme inhib•
itor to chronic monotherapy. After the addition of hydro•
chlorothiazide, mean aldosterone values increased to the 
respective baseline (day - 1) on days 28 and 29 in group 
C and somewhat above the baseline (p < 0.05) in group E. 
Adverse effects. In group C (captopril sequence), one 
patient developed a marked alteration in taste sensation on 
day 20 of the study while receiving captopril and hydro•
chlorothiazide. The patient continued in the study through 
day 28 and the taste alteration persisted. She was excluded 
from day 29 because of low blood pressure (124/64 mm 
Hg) and light-headedness on day 28. The taste disturbance 
dissipated slowly after drug discontinuation. Another patient 
in group C developed dizziness, weakness and hypotension 
on day 29 for a 6 hour period. In group E (enalapril se•
quence), one patient complained of light-headedness for a 
short period of time, 2 to 3 hours after dosing, on both days 
14 and 15; this was not accompanied by profound hypo•
tension. One patient, a black woman, was eliminated from 
the study because of hypotension while receiving enalapril 
and hydrochlorothiazide. She had a marked response to 
enalapril on day 1 (from a mean time-averaged seated di•
astolic blood pressure of 110 mm Hg with placebo to 86 
mm Hg with enalapril). By day 14, however, her blood 
pressure had returned to near baseline (106 mm Hg) and 
her urinary sodium excretion had increased by 50 mEq from 
day - 1 and day 1 values. The addition of captopril on day 
15 did not result in a further decrease in blood pressure 
(mean 106 mm Hg). With the addition of hydrochlorothia•
zide, the patient developed marked dizziness, diaphoresis 
and nausea on day 18 (3 days of combined treatment) and 
her blood pressure was 86/50 mm Hg. Her drugs were 
withheld for 2 days during which time her blood pressure 
returned to baseline values and treatment with enalapril and 
hydrochlorothiazide was restarted. Four days later (day 25), 
she again developed dizziness, nausea and hypotension and 
was withdrawn from the study. 
No significant changes in laboratory screening tests for 
organ function were observed during the study. No treat•
ment-related changes in white blood cell counts or urinary 
protein were observed in these patients with normal renal 
function during the month of converting enzyme inhibitor 
treatment. 
Response predictors. The analysis of variance proce•
dures in both groups C (captopril) and E (enalapril) identified 
a significant racial effect in mean seated diastolic blood 
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Figure 3. Mean ( + I SD) serum angiotensin-con-
verting enzyme (ACE) activity (A), plasma renin 
activity (B) and plasma aldosterone concentration 
(C) on inpatient study days in group C (captopril 
sequence, closed bars) and group E (enalapril se-
quence, open bars). Within group comparisons. p 
< 0.05 for: * = from day - I (placebo); + = 
from days - I, I, 14 and 15; and t = from day 
28 . 
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pressure responses, White patients responded better than 
blacks, 
Regression analyses. with the changes in seated diastolic 
blood pressure in the short (day - 1 minus day 1) or long 
(day - 1 minus day 14) term in both groups as the dependent 
variable, failed to show a significant relation with the mean 
seated diastolic pressure on day - 1. That is, the initial 
blood pressure was a poor predicator of the response to the 
converting enzyme inhibitors in this study. Other factors 
that were either poor or inconsistent individual predictors 
of acute or chronic blood pressure response in both groups 
were pretreatment plasma renin activity, change in plasma 
renin activity from pretreatment, pretreatment plasma al•
dosterone concentration and change in plasma aldosterone 
concentration from pretreatment. 
Discussion 
Before entry into this double-blind randomized study, 
the 20 hypertensive patients with normal renal function were 
classified into a treatment group (captopril or enalapril) ac•
cording to the degree of their blood pressure elevation and 
their race, because these factors had been identified by others 
(16,17) as possibly influencing a comparison of drug effects. 
Before the study, moderate sodium intake was prescribed 
and complied with based on evaluations of urinary sodium 
excretion. The doses were purposely selected near the upper 
recommended ranges for the two oral converting enzyme 
inhibitors to minimize differences in effects due strictly to 
dissimilar potencies. Comparable blood pressure reduction 
might have been achieved with lower doses of both agents. 
Although enalapril has been given once daily in patients 
with hypertension (2), some patients require twice daily 
dosing and, for this reason, twice daily dosing was selected 
for our protocol. 
Antihypertensive effects. Under these study condi•
tions, no clinically or statistically significant differences 
between the antihypertensive effects of captopril and ena•
lapril were apparent. On day 14, both agents decreased mean 
seated diastolic blood pressure by 7 or 8 mm Hg from the 
value with placebo in their respective group. No additional 
decrease in blood pressure was observed when a single dose 
of enalapril was added after chronic captopril therapy or 
vice versa (day 15), suggesting that these agents may have 
a similar mechanism of action. Because the acute and chronic 
hypotensive effects of these agents were similar, it is un•
likely that continued administration of these agents in com•
bination would have resulted in a further decrease in blood 
pressure. When captopril or enalapril was combined with 
hydrochlorothiazide, however, a further decrease in blood 
pressure was achieved in each group; the effect of this com•
bination therapy in each group was comparable (that is, an 
additional 7 to 8 mm Hg decrease in mean seated diastolic 
blood pressure in each group by day 28). Finally. after the 
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alternate converting enzyme inhibitor was added to either 
combination (converting enzyme inhibitor plus diuretic agent), 
there was no difference in the antihypertensive response 
between the two groups of patients, although there was a 
further decrease in blood pressure compared with the blood 
pressure measured with each drug regimen alone. This fur•
ther decrease in blood pressure on day 29 merits further 
consideration. 
Role of sodium intake and excretion. The hypotensive 
response to the angiotensin-converting enzyme inhibitors is 
dependent on the sodium and volume status of the patient 
(12,19). On study days -1,1,14 and 15, the subjects had 
similar 24 hour urinary excretion, indicating moderation in 
their sodium intake and no notable natriuresis. When our 
patients were studied in the clinical pharmacology unit, they 
were given a sodium-restricted diet. After beginning diuretic 
treatment, urinary sodium excretion increased markedly and 
remained increased before readmission to the unit on day 
28. On the basis of other trials (20) with diuretic drugs we 
have undertaken in which sodium consumption was moni•
tored, this increase in sodium excretion after 12 days of 
combination therapy was thought to be, in large part, a 
reflection of increased sodium intake rather than continued 
diuretic-induced natriuresis. In the unit, the patients were 
again placed on a prescribed diet for 2 days, which resulted 
in a marked decrease in sodium excretion on day 29 in 
comparison with the same period on day 28. This change 
in sodium intake probably accounted for the additional de•
crease in blood pressure observed on this day (day 29) on 
addition of the alternate converting enzyme inhibitor in each 
group. This explanation is more plausible than a mechanistic 
difference existing between these agents that was only man•
ifested when the patients were receiving a diuretic drug, 
and it further demonstrates the ability of increased sodium 
intake to counteract the antihypertensive effect of converting 
enzyme inhibitors (12,19). This was also evident by eval•
uation of the urinary sodium excretion in the black woman 
in group E who initially had a marked decrease in blood 
pressure in response to enalapril with a return to near base•
line value by day 14, only to have hypotension develop 
when diuretic treatment was added. 
Captopril versus enalapril: animal studies. Mecha•
nistic differences between captopril and enalapril have pre•
viously been postulated, mainly on the basis of animal stud•
ies (4-10). In the spontaneously hypertensive rat, enalapril 
(MK-421) was more potent than captopril in decreasing 
blood pressure, yet equally active in its ability to block 
angiotensin I pressor responses (4). In the pithed sponta•
neously hypertensive rat, captopril significantly inhibited 
pressor responses to sympathetic nerve stimulation and nor•
epinephrine, whereas enalapril did not (5). Because both 
drugs were antihypertensive in this rat model, it was sug•
gested that only captopril was interfering with sympathetic 
responses. Such differences in the antihypertensive activity 
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of the converting enzyme inhibitors in animals has been 
proposed (5) to result from differential penetration and in•
hibition of converting enzyme activity in the arterial vascular 
wall as opposed to the serum alone. This hypothesis ap•
peared to be confirmed in intact spontaneously hypertensive 
rats and in the isolated perfused kidney, where captopril 
abolished vascular responsiveness to norepinephrine in the 
renal artery to a much greater extent than did enalapril 
(6,8,9). Differences in potency among converting enzyme 
inhibitors in pressor responses to infusion of angiotensin I 
also have been reported (10) in the conscious spontaneously 
hypertensive rat, even though their hypotensive effect was 
similar. On the other hand, in normotensive men both cap•
topril and enalapril were equally effective in blocking pres•
sor responses to exogenous angiotensin I, although with a 
different milligram potency (20). 
Captopril versus enalapril: human studies. In a 
double-blind, parallel comparison study of 32 patients re•
ceiving hydrochlorothiazide, 50 mg/day, Thind et al. (13) 
recently reported that enalapriI. 5 to 20 mg twice daily, was 
superior to captopriI. 25 to 100 mg three times daily, in 
decreasing supine and upright diastolic blood pressure. These 
findings are in contrast to those of our study. The study of 
Thind et al. can be criticized because 1) the investigators 
did not specify at what time blood pressure measurements 
were made in relation to the previous dose; 2) no evaluation 
of dietary sodium intake was made, which could have led 
to apparent treatment differences; 3) more patients in the 
enalapril group than in the captopril group were hypoka•
lemic on treatment with hydrochlorothiazide alone (n = 5 
and n = 1, respectively), perhaps indicating a greater stim•
ulation of the renin-angiotensin-aldosterone system in this 
group, which could affect the response to converting enzyme 
inhibition; and 4) there was no assessment of biochemical 
correlates of the blood pressure response, as performed in 
our study. 
In contrast, Lewis et al. (14), in a very similar study, 
reported a greater initial response with captopril than with 
enalapril added to hydrochlorothiazide but reported equiv•
alent efficacy with more prolonged treatment. Moreover, 
Chrysant et al. (15) noted no difference between these agents 
in 20 patients studied under essentially the same protocol. 
Furthermore, in a review article on enalapril, Davies et al. 
(22) discussed an unpublished, large scale, comparative trial 
in 161 patients with supine diastolic blood pressures of 100 
to 120 mm Hg initially treated with 50 mg/day of hydro•
chlorothiazide. Doses of enalapril in this study were 10 to 
40 mg/day, whereas those of captopril were 75 to 300 mg/day, 
which is similar to the doses in the studies of Thind (13), 
Lewis (14), Chrysant (15) and coworkers. The results re•
ported by Davies et al. indicate that captopril and enalapril 
produced very similar and not significantly different anti•
hypertensive effects in combination with hydrochlorothia•
zide. On the basis of the similarity of the reported study 
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designs, it appears that the study groups of Thind (13), 
Lewis (14), Chrysant (15) and coworkers were subgroups 
of the larger study (21) and that the reported differences 
were not confirmed by total group analysis. Our data on 
day 28 (hydrochlorothiazide plus angiotensin-converting en•
zyme inhibitor) agree with those reported by Davies et al. 
(22). In addition, our trial evaluated these agents as mono•
therapy and also found no apparent differences in efficacy. 
Factors affecting hypotensive response to either 
agent. Thus. despite results suggesting mechanistic differ•
ences in animal and human studies. on the basis of our study 
captopril and enalapril appear to be equally effective in 
decreasing blood pressure in hypertensive patients as long 
as maximal inhibition of serum angiotensin-converting en•
zyme acitivity is achieved. In this regard, our own initial 
suggestion, based on a retrospective comparison (23,24), 
that these agents may have dissimilar antihypertensive ac•
tivity in humans was more than likely due to differences in 
converting enzyme inhibitor potency or the sodium status 
of the patients. Control of these variables led to a more 
precise evaluation of drug effects in the present study. 
Our study also suggests no essential difference in the 
mechanism (or mechanisms) by which captopril and ena•
lapril decrease the blood pressure. This conclusion is further 
substantiated by their similar effects on serum converting 
enzyme and plasma renin activities and plasma aldosterone 
concentrations, whether alone or in combination with a di•
uretic agent. The observed changes are compatible with 
those noted to occur with converting enzyme inhibitors (1,2). 
In addition to indicating similar effects of the two inhibitors, 
our data, as well as those of others (25), support two general 
concepts about these agents. One is that maximal suppres•
sion of the renin-angiotensin system, through inhibition of 
serum angiotensin-converting enzyme, corresponds with the 
maximal antihypertensive effect of the inhibitors. Second, 
if other mechanisms are involved in the antihypertensive 
effect of the angiotensin-converting enzyme inhibitors, they 
are probably secondary effects. For example, a decrease in 
angiotensin II concentrations by captopril could thereby have 
produced decreased vascular responsiveness to endogenous 
norepinephrine (26,27). 
Other findings. Additional aspects of our study are wor•
thy of note. As expected, heart rate did not change after 
treatment with either converting enzyme inhibitor. The in•
creases noted on days 28 and 29 were those commonly 
observed with diuretic agents alone. There was an overall 
statistical difference in the antihypertensive effect of the 
converting enzyme inhibitors in the black as compared with 
the white patients, compatible with our prestudy assumption 
(16). Pretreatment plasma renin activity, however, was not 
predictive of the magnitude of the hypotensive response to 
either converting enzyme inhibitor. In this regard, the so•
dium and volume status of black patients may be a more 
important factor than the level of plasma renin activity. In 
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contrast to data in a previous report (17), the level of pre•
treatment blood pressure did not correlate with the magni•
tude of blood pressure reduction after administration of either 
converting enzyme inhibitor. Serum potassium did not change 
significantly in either group during combined converting 
enzyme inhibitor and diuretic treatment, suggesting potas•
sium-sparing effects of this combination, similar to our pre•
vious findings (23). Finally, the changes in plasma renin 
activity and plasma aldosterone concentrations from pre•
treatment values after the two converting enzyme inhibitors 
were administered did not correlate well with their anti•
hypertensive effects, suggesting that other factors affecting 
these biochemical indexes make them less than desirable in 
evaluating the effectiveness of these agents. 
Conclusions. We found that captopril, 200 mg twice 
daily, and enalapril, 20 mg twice daily, decreased blood 
pressure to a comparable degree in patients with mild to 
moderate essential hypertension. This was true whether the 
agents were used alone or in combination with hydrochlo•
rothiazide. Combining captopril and enalapril did not result 
in a further decrease in blood pressure. There was a greater 
blood pressure reduction in white than in black patients with 
the converting enzyme inhibitors. The apparent lack of dif•
ferences in blood pressure effect was paralleled by similar 
changes in measured humoral factors after administration 
of either drug. Both drugs were well tolerated. Although 
there were a few more side effects (for example, loss of 
taste) with captopril than with enalapril, careful interpre•
tation of these results is suggested because of the small 
sample size, the low incidence of adverse effects and the 
absence of renal dysfunction, which has been implicated as 
a risk factor for captopril side effects (1). Finally, large 
scale trials would not be expected to show significant dif•
ferences between the efficacy of these two converting en•
zyme inhibitors used either alone or in combination with 
hydrochlorothiazide. 
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Ghassem Lanjani, PharmD for his preparation of the figures and posthu•
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